Skip to main content
AmigoFish

Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

From Pharmaceutical Executive · · 3 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.

Back to Pharmaceutical Executive · Report a problem